Ocean Biomedical Publishes Breakthrough EGFR-Mutant Lung Cancer Data and Plans to Engage FDA on Regulatory Pathway

February 10, 2025

DENVER, Colo., Feb 10, 2025 (247marketnews.com)- Ocean Biomedical (NASDAQ:OCEA) published data regarding its proprietary cancer immunotherapy candidates. in combination with tyrosine kinase inhibitors (TKIs). The results represent a significant breakthrough in non-small cell lung cancer (NSCLC) treatment. The findings suggest that these immunotherapy candidates not only work synergistically with TKIs, such as gefitinib and osimertinib to suppress tumor growth, but may be especially effective for patients whose tumors have become resistant to standard treatments.

Dr. Jack A. Elias, Ocean Biomedical’s Scientific Co-founder, published these findings in collaboration with researchers at Yale University and Brown University in Translational Oncology.

Ocean’s immunotherapy candidates’ ability to overcome resistance to osimertinib is groundbreaking. Resistance to TKIs is a major hurdle in the treatment of EGFR-mutant NSCLC, and this novel approach could provide a much-needed solution. By restoring sensitivity to treatment, Ocean’s immunotherapies could prolong the efficacy of TKIs, offering patients additional treatment time before moving to more aggressive therapies.

Dr. Chirinjeev Kathuria, Ocean’s Board Chair and Co-Founder, stated, “Our latest findings open an exciting new avenue in lung cancer treatment by demonstrating a potential solution to osimertinib resistance, a critical unmet need for patients worldwide. With the industry shifting towards next-generation bispecific antibodies, Ocean Biomedical is strategically positioned to capitalize on this momentum in a variety of diseases including NSCLC, malignant melanoma and glioblastoma. The recent $588 million acquisition of LaNova’s LM-299 validates the enormous market potential in this space, and we believe our innovative immunotherapy platform could drive significant value for both patients and investors.”

The synergy between Ocean’s immunotherapy candidates and TKIs like osimertinib and gefitinib could significantly enhance the therapeutic effect of existing drugs. By combining immune-modulating therapies with targeted cancer treatments, patients may reduce tumor progression and potential remission.

This research highlights the novel role of CHi3L1 in EGFR-mutant cancers, with Ocean’s antibody able to suppress its activity. CHi3L1 is a protein that could play a key role in cancer progression, and its inhibition is a promising strategy for reducing tumor size and combating resistance. This marks an important innovation in the field of cancer immunotherapy.

Ocean Biomedical’s development of bispecific antibodies targeting CHi3L1 alongside PD-1 or CTLA4 is another significant step forward in cancer treatment. Bispecific antibodies allow for the targeting of multiple cancer pathways simultaneously, which may lead to more effective treatments. The growing industry interest in bispecific antibodies, exemplified by Merck’s acquisition of LaNova’s LM-299, underscores the potential of this therapeutic class. Ocean’s efforts to develop such antibodies for NSCLC, melanoma, and glioblastoma could place them in a prime position within the oncology space.

The Company is positioning its lead oncology program for multiple therapeutic applications:  Standalone therapy for EGFR-mutant NSCLC, Combination therapy with existing TKIs to extend their effectiveness, and Salvage therapy to restore treatment efficacy in resistant tumors.

This versatility could make Ocean’s therapies valuable in multiple stages of cancer treatment, offering more comprehensive solutions for patients with EGFR-mutant NSCLC.

Ocean Biomedical is planning to engage with the FDA regarding the regulatory pathway for clinical development. This represents an important next step toward getting its innovative therapies into human clinical trials. The FDA’s approval of a regulatory pathway is crucial to progressing the therapies through the necessary clinical stages to reach patients.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (OCEA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.